Exhibit 99.2 Letter to Stockholders May 13, 2024 Dear Harrow Stockholders: Today marks the beginning of the 20 week of 2024 and the 134 day into the second year of Harrow’s current Five-Year Strategic Plan. This year remains focused on three key operational initiatives: (1) building a formidable dry eye disease franchise, including successfully launching VEVYE; (2) continuing to lay the foundation for Harrow’s retina franchise with IHEEZO and TRIESENCE; and (3) stabilizing ImprimisRx and our recently acquir ...